title: Phase II trial of mitogauzone in malignant primary brain tumors.
abstract: Sixteen patients with primary malignant brain tumors, recurrent or progressive after surgery and radiation therapy, were treated with mitoguazone. Starting dose was 500 mg/m2 iv on a weekly schedule. In 15 evaluable patients no tumor regressions were observed. Four patients had stabilization of disease.
mesh_terms: D000328:Adult; D001932:Brain Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D008935:Mitoguazone / Q000009:adverse effects / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000139:chemically induced; D013280:Stomatitis / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D006146:Guanidines; D008935:Mitoguazone